[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:hyperacute-graft-rejection":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":62,"states":63},"Hyperacute graft rejection",8,5,[8,16,23,29,35,41,49,56],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06918990","Treatment of Antibody-Mediated Rejection (ABMR) With CarBel",[12],"Phase 1","RECRUITING","2026-08-26T02:18:12.612955Z","2026-07-05T05:32:16.722734Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT06744647","Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation",[20],"Phase 2","2026-08-03T02:49:28.132118Z","2026-05-05T02:47:14.272205Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT06990711","A Phase 1 Clinical Trial of Siltuximab for the Treatment of Antibody-Mediated Rejection After Lung Transplantation",[12],"2026-08-26T02:18:13.438956Z","2026-05-05T02:43:28.298280Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT02812290","Diagnostic and Therapeutic Applications of Microarrays in Lung Transplantation",[],"2026-08-26T02:17:22.153941Z","2026-05-13T02:55:06.102450Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT05004493","Biorepository and Registry for Plasma Exchange Patients",[],"2026-08-26T02:18:18.766496Z","2026-05-13T02:55:06.276731Z",{"nct_id":42,"title":43,"phases":44,"status":46,"updated_at":47,"content_modified":48},"NCT07444489","A Study to Learn More About the Long-Term Safety and Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR) or Microvascular Inflammation (MVI) (TRANSCEND\u002FTRANSPIRE LTE)",[45],"Phase 3","ENROLLING_BY_INVITATION","2026-08-26T02:16:03.788292Z","2026-07-05T05:32:16.681628Z",{"nct_id":50,"title":51,"phases":52,"status":53,"updated_at":54,"content_modified":55},"NCT06503731","A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection (AMR)",[20],"ACTIVE_NOT_RECRUITING","2026-08-03T02:22:55.112436Z","2026-05-05T02:43:28.822803Z",{"nct_id":57,"title":58,"phases":59,"status":53,"updated_at":60,"content_modified":61},"NCT06685757","A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)",[45],"2026-08-03T02:17:17.775722Z","2026-05-05T02:43:28.820647Z",[],[64,67,70,74,77,80,83,86,90,93,96,99,102,105],{"state":65,"count":6,"slug":66},"California","california",{"state":68,"count":6,"slug":69},"Ohio","ohio",{"state":71,"count":72,"slug":73},"Missouri",4,"missouri",{"state":75,"count":72,"slug":76},"North Carolina","north-carolina",{"state":78,"count":72,"slug":79},"Virginia","virginia",{"state":81,"count":72,"slug":82},"Washington","washington",{"state":84,"count":72,"slug":85},"Wisconsin","wisconsin",{"state":87,"count":88,"slug":89},"Alabama",3,"alabama",{"state":91,"count":88,"slug":92},"Arizona","arizona",{"state":94,"count":88,"slug":95},"Illinois","illinois",{"state":97,"count":88,"slug":98},"Nebraska","nebraska",{"state":100,"count":88,"slug":101},"New Jersey","new-jersey",{"state":103,"count":88,"slug":104},"Pennsylvania","pennsylvania",{"state":106,"count":88,"slug":107},"Texas","texas"]